Introduction {#S0001}
============

With the widespread use of combination, antiretroviral therapy (ART) for the prevention of mother-to-child transmission (PMTCT) of HIV, vertical transmission rates have dwindled to \<2% \[[@CIT0001]--[@CIT0003]\]. The tremendous success of PMTCT has resulted in a diminishing population of perinatally infected children on the one hand and a mounting number of HIV-exposed uninfected (HEU) children on the other. It is estimated that approximately 20% of all infants born in sub-Saharan Africa are born HEU \[[@CIT0004]\].

Households comprising HIV-infected women and HEU children often face significant socio-economic stressors with limited healthcare access, high levels of perceived stigma and low levels of psycho-social support \[[@CIT0005]--[@CIT0007]\]. Disclosure of a child\'s HEU status, by definition, requires disclosure of maternal HIV status, and this may be difficult given the mother\'s right to privacy and concern for safety, particularly with continuing stigma around HIV. Disclosure of a mother\'s HIV status to her children has been low with rates ranging from 20 to 60% in the United States \[[@CIT0008],[@CIT0009]\] and 40 to 50% in sub-Saharan Africa \[[@CIT0005],[@CIT0010]\]. While much of the disclosure literature has focused on a mother\'s disclosure of her HIV status to her children, exploring potential benefits to a mother\'s own health \[[@CIT0008],[@CIT0011]\], little has been published on the disclosure of a child\'s *in utero* exposure to HIV and antiretroviral medications (ARVs) and whether this has direct risks or benefits to the child\'s health \[[@CIT0012]\].

The oldest of HEU children are now reaching adolescence and early adulthood, an important transition period often marked by concerns around diminished healthcare access and utilization \[[@CIT0013]\]. As HEU adolescents transition from paediatric to adult healthcare, many assume responsibility for their own healthcare decisions during an already complex phase of cognitive, psychosocial and developmental changes. This responsibility requires knowledge of their medical history, which may include information about perinatal exposures such as exposure to *in utero* HIV/ARV. Today, we face unknowns regarding the long-term safety of intrauterine HIV/ARV exposure into adulthood and an increasingly large and aging population of HEU children. At the intersection of these issues, the landscape of HIV disclosure is beginning to consider not only benefits/harms for the mother and her family regarding disclosure of maternal HIV status but also benefits/harms for the child regarding disclosure of a child\'s perinatal HIV/ARV exposure status. Researchers evaluating the long-term safety of intrauterine HIV/ARV exposures through prospective cohort studies require long-term monitoring of HEU children into adulthood necessitating consent from such individuals when they turn 18, resulting in a need to disclose perinatal HIV/ARV exposures to the HEU participant. Clinicians assuming the healthcare of HEU adolescents may struggle with how to best monitor HEU patients in the setting of a lack of conclusive data on the long-term risks of intrauterine HIV/ARV exposures. HEU adolescents and their mothers may have competing desires for privacy due to persistent stigma and the need to avert other psychosocial harms. Adolescents transitioning to adult care may not be fully emotionally and mentally prepared to assume responsibility for their own health as this can be an unstable period of experimentation and individuation which supersedes desires to participate in consistent healthcare. In this article, we summarize the arguments for and against disclosure of intrauterine HIV/ARV exposure to HEU children/adolescents.

Discussion {#S0002}
==========

Monitoring of HEU children: current guidelines {#S0002-S20001}
----------------------------------------------

We begin our discussion with a related but separate question involving whether HEU children merit long-term monitoring, since the answer to this question has direct impact on whether disclosure of a child\'s intrauterine HIV/ARV exposure should occur. We systematically reviewed all English, French and Spanish articles identified in a PubMed/Medline database up to July 2016 on guidelines for the monitoring of HEU children and contacted several key in-country researchers leading surveillance and research initiatives in this area. While there is no consensus on the type of monitoring which should occur, several countries have developed systems and guidelines ([Table 1](#T0001){ref-type="table"}). Wide variability in the recommended duration and intensity of longitudinal observation exists, perhaps due to the fact that this is a rapidly evolving area where emerging needs of HEU children are slowly rising to the forefront. Mechanisms of monitoring encompass registry/surveillance programmes and national research cohorts, depending on available resources and competing national health priorities.

###### 

Surveillance and monitoring of HIV-exposed uninfected children in selected countries

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                  Current HIV Perinatal registry and surveillance linkage systems                                                                                                                                                    Key research cohorts                                                                                                                                                                                                                                                                                                                                                      
  --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  United States   None nationally currently; state-dependent Perinatal HIV Exposure Reporting Programs; Previous Enhanced Perinatal Surveillance (EPS) Program ended 2011; some state-dependent linkage to state cancer registries   State-Dependent; Prenatal & Intrapartum Data; Postnatal Data limited to infection status, postnatal ARVs, death, birth defect outcomes; New Jersey state with programme linking to state cancer registry   12--18 months for EPS; Up to 16 years for state linkage programme to cancer registry   PHACS (SMARTT)\          ≥4 years                                       "Follow-up of children with exposure to ARVs should continue into adulthood because of the theoretical concerns regarding the potential for carcinogenicity of nucleoside analogue ARV drugs. Long-term follow-up should include annual physical examinations of all children exposed to ARV drugs. Innovative methods are needed to provide follow-up of infants, children, and youth with in utero exposure to ARV drugs. Information regarding such exposure should be part of ongoing permanent medical records for children, particularly those who are uninfected." (DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, 2014)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       PACTG/\                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       IMPAACT 219/219c                                                        

  Canada          Canadian Perinatal HIV Surveillance Program                                                                                                                                                                        Prenatal & Intrapartum Data; Postnatal Data limited to infection status, postnatal ARVs, death, major birth defects                                                                                        18 months                                                                              CARMA, CMIS              CARMA (range up to 15 years); CMIS (2 years)   "Long-term follow-up and annual physical examinations, into adulthood, of HIV-uninfected infants exposed in utero and perinatally to antiretroviral medications is now recommended by the DHHS because of the potential carcinogenicity of the nucleoside analogs. Finally it is important to ensure continued psychosocial support for HIV-exposed uninfected children and their families." (Prevention of Vertical HIV Transmission and Management of the HIV-exposed infant in Canada in 2014, CPARG & ID-SOCG)

  France          Surveillance programme linking EPF and French National Cancer Registry                                                                                                                                             Anonymous linkage system between EPF and French National Cancer Registry                                                                                                                                   Up to 15 years                                                                         EPF                      18--24 months                                  "If an HIV-exposed uninfected infant is asymptomatic, follow-up ends at 18--24 months. Follow-up should continue as necessary for unexplained symptoms, particularly neurological symptoms. There is, to date, no active program for the long term follow-up of asymptomatic HIV-exposed uninfected infants. Long term follow-up of symptomatic children may be justified and should be guided by best clinical practices. Families should alert the child\'s physician and/or the physician who treated the child during the first months of life of any significant clinical events." (Medical Management of Persons Living with HIV, Report from Expert Panel of CNS and ANRS, 2013)

  England         NHSPC; Flagging system to link NSHPC and death or cancer events in the national Health and Social Care Information Center (HSCIC)                                                                                  Prenatal & Intrapartum Data; Postnatal Data limited to infection status, postnatal ARVs, death, and cancer events                                                                                          Until HIV-non-infection documented (Range between 6 and 18 months) for NHSPC           CHART                    --                                             "It is the responsibility of clinicians caring for women with HIV and their children to report them prospectively to the NSHPC. Aggregated data tables from the UK and Ireland of antiretroviral exposure and congenital malformations are regularly sent to the Antiretroviral Pregnancy Registry. Individual prospective reports should also be made to the Antiretroviral Pregnancy Registry antenatally with post-natal follow-up." (Management of HIV Infection in Pregnant Women, 2014 interim update, British HIV Association)

  Spain           None                                                                                                                                                                                                               --                                                                                                                                                                                                         --                                                                                     NENEXP                   18 months                                      "... the potential long-term toxicity in healthy exposed infants and the continuing emergence of new ARVs make it advisable to devise a mechanism whereby the identification and registration of potential adverse long-term effects of such exposures may be recorded. The Spanish Society of Pediatric Infectious Diseases recommends the creation of an anonymous national database supported by health authorities for this purpose. This database would require informed consent of the legal guardian of the infant (and the patient\'s own later) prior to inclusion in it. Unfortunately, these recommendations are in contrast with the reality of current practices in Spain where some specialized centers end monitoring of these patients at the time of seronegativity, others at 5 years of age, and still others follow throughout childhood." (Recommendations by the Spanish Society of Pediatric Infectious Diseases for the follow-up of the child exposed to HIV and to ARV drugs during pregnancy and the neonatal period, 2012)

  South Africa    New national registry beginning in 3 provinces including Western Cape                                                                                                                                              Basic perinatal and postnatal data, infection status, growth, TB symptom screening, developmental milestones assessment, significant events                                                                To be defined                                                                          CDC-funded PMTCT Study   18 months                                      "Ideally all mothers and their infants should receive health care at the same consultation regardless of service point. The mother should understand the treatment and follow-up plan for herself and her infant. The RTHB should be completed prior to discharge after delivery, including recording HIV treatment/prophylaxis interventions received by mother during pregnancy, maternal illnesses, infant HIV prophylaxis and intended feeding method. The 1st postnatal visit is scheduled for day 3 but should take place within 6 days of life at the health facility." Scheduled visits for infant follow-up should occur at 6, 10, and 14 weeks, monthly after 14 weeks until again at 6, 9, 12, and 18 months. (The South African Antiretroviral Treatment Guidelines 2013 -- PMTCT Guidelines: Revised March 2013)

  Thailand        National Surveillance Program of the Thai Ministry of Public Health                                                                                                                                                Prenatal & Intrapartum Data; Postnatal Data limited to infection status, postnatal ARVs, death                                                                                                             12--18 months                                                                          --                       --                                             "The goals of the program are to reduce MTCT, provide health promotion for infants born to HIV-infected mothers, and provide appropriate medical treatment for parents in order to reduce the risk of infants or children being orphaned. Comprehensive care for HIV-infected women and family includes the following services: 1) Standard postpartum care should be provided, 2) General health promotion, e.g. nutritional support and exercise, should also be provided. 3) All postpartum women should be referred to internists for standard HIV treatment and care. Psychological and social supports needed for HIV-infected families may include the management of postpartum depression, psychosocial support for child rearing, and long-term family care." (Thai National Guidelines for the Prevention of Mother-to-Child Transmission of HIV: March 2010)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANRS=Agence nationale de recherches sur le SIDA et les hépatites virales; ARV=antiretroviral; CARMA=Canadian Institutes of Health Research Team Grant on HIV Therapy and Aging; CDC=Centres for Disease Control and Prevention; CHIPS=Collaborative HIV Paediatric Study; CMIS=Centre maternel et infantile sur le SIDA (Canadian Maternal Child Cohort); CNS=Conseil National du SIDA; CPARG=Canadian Paediatric and Perinatal AIDS Research Group; DHHS=Department of Health and Human Services; EPF=Enquête Périnatale Française (French Perinatal Cohort); HEU=HIV-exposed uninfected; ID-SOCG=Infectious Disease Committee of the Society of Obstetricians and Gynaecologists of Canada; NENEXP=Estudio clinico-epidemiologico de las parejas madre-hijo expuestas al VIH y/o a los fármacos antiretrovirales (Spanish Perinatal Cohort Study); NSHPC=National Study of HIV in Pregnancy and Childhood; PHACS=Pediatric HIV/AIDS Cohort Study; PMTCT=Prevention of Mother To Child Transmission; RTBH=Road-To-Health-Booklet; SMARTT=Surveillance Monitoring for ART Toxicities Study in HIV-uninfected Children Born to HIV-infected Women.

The U.S. Department of Health and Human Services recommends that HEU children be followed into adulthood due to the potential for carcinogenicity from nucleoside analogue ARVs \[[@CIT0014]\]; Canadian guidelines mirror this and appeal for the psychosocial support of HEU children \[[@CIT0015]\]. US guidelines also acknowledge a need for "innovative methods" to provide follow-up of these children and encourage that information regarding *in utero* HIV/ARV exposure be "part of ongoing permanent medical records for children." In addition to several HEU research cohorts in both countries, the United States also recently reported a linking system in one state to match subjects from the Perinatal HIV Surveillance database and the state\'s cancer registry to monitor malignancy risk in HEU children \[[@CIT0016]\]. A similar linkage system had been developed earlier in France, where the national cancer registry was linked in an anonymized fashion \[[@CIT0017],[@CIT0018]\] to the major research cohort with longitudinal monitoring of HEU infants until 18 to 24 months \[[@CIT0019]--[@CIT0021]\]. The UK also has a national surveillance system of HIV-infected pregnant women and their infants (National Study of HIV in Pregnancy and Childhood, or NSHPC), which follows HEU children up to 18 months. National death and cancer event data in the UK have, in turn, been linked to data in the NSHPC to monitor death and cancer rates in HEU children \[[@CIT0022],[@CIT0023]\]. In more resource-constrained settings, such as South Africa and Thailand, national guidelines recommend routine follow-up of HEU infants until approximately 18 months \[[@CIT0024],[@CIT0025]\]. A South African pregnancy and HEU surveillance registry is being launched, which will ultimately include three provinces -- KwaZulu-Natal, Gauteng and the Western Cape.

The differences in national guidelines on HEU longitudinal monitoring may be attributed to the differences in healthcare and research resources between countries. Regrettably, areas where high numbers of HIV/ARV-exposed pregnancies occur are also areas where healthcare, research and public health resources may be the most constrained. Despite the lack of consensus on the type of monitoring which HEU children merit, there does appear to be general agreement that some form of follow-up of HEU children is warranted \[[@CIT0026]\] for the following reasons: 1) The type and timing of ARV exposures continue to evolve, at times outpacing research, making continued surveillance essential, 2) There are still many unknowns regarding long-term effects of this exposure. Given this, we now outline arguments in favour of and against disclosing perinatal HIV/ARV exposure status.

The case for disclosure {#S0002-S20002}
-----------------------

The key arguments in favour of disclosure revolve around the assumption that there are substantial benefits (psychosocial and physical) for the child, HIV-infected mother and even other family members. In addition, disclosure may facilitate the conduct of large prospective HEU research cohorts in long-term monitoring, ultimately serving a critical public health function ([Table 2](#T0002){ref-type="table"}).

###### 

Major arguments for and against disclosure

  Domain of consideration   For disclosure                                                                                                                          Against disclosure
  ------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Psychosocial              Improves psychological health of mother and child                                                                                       Worsens psychological health of mother and child -- increase stigma and create increased stressors on an already fragile family environment
                            Aids in transition and autonomy from childhood to adulthood healthcare                                                                  Creates a layer of unnecessary complexity during a time of transition when the adolescent may not be prepared to properly understand this exposure
  Physical Health           Averts potential physical harm from long-term complications; early signals presented in current data are enough to warrant disclosure   Largely reassuring evidence that no physical harm with major early outcomes; not enough evidence of harm to see a benefit
  Research/Public Health    Improves ability to continue long-term monitoring of more detailed outcomes in prospective research cohorts                             Minimal ability to sustain long-term prospective HEU cohorts in the majority of the world. Surveillance programmes with linkage systems for the monitoring of major events in place and does not require disclosure

### Psychosocial considerations

Despite the paucity of literature describing the impact of disclosure of a child\'s perinatal HIV/ARV exposure, several studies suggest positive effects on family relationships when disclosure of maternal HIV status to children occurs \[[@CIT0011],[@CIT0027],[@CIT0028]\]. The Amagugu study in South Africa reported significant reduction in parental stress and child emotional/behavioural problems after an intervention to aid in disclosure of maternal HIV status \[[@CIT0027]\]. In addition to higher family cohesion \[[@CIT0029]\], United States studies have demonstrated lower levels of aggressiveness, poor self-esteem \[[@CIT0011]\] and problem behaviours \[[@CIT0028]\] in children whose mothers had disclosed compared to those who had not.

### Physical health considerations

Clear physical harms from intrauterine HIV/ARV exposure would necessitate disclosure to the HEU individual. Several scientific arguments may be made to demonstrate current concerns for physical harms which may exist as a result of the exposure. First, developing theories on the origins of disease have suggested that foetal programming and the *in utero* milieu have a durable effect on the long-term health of an individual \[[@CIT0030]\]. The *in utero* period represents a critical window during which changes may alter the biological setting of a foetus, thus placing the foetus at risk for future disease well into adulthood. For example, direct intrauterine toxins have the capacity to cause harmful effects even decades after the initial exposure, as in the case of antenatal diethylstilboestrol exposure and the increased risk of cervical, vaginal and breast cancer as well as infertility in adulthood \[[@CIT0031]\]. Furthermore, *in utero* effects may present much later in life \[[@CIT0032]\], such as with increased schizophrenia risk from maternal influenza and toxoplasmosis during pregnancy \[[@CIT0033],[@CIT0034]\] or adult insulin resistance and cardiovascular disease from intrauterine growth restriction \[[@CIT0035]\]. These long-term effects on neurobiological and metabolic pathways may not present with clear disease early in life but as the individual progresses through life and other adult exposures increase, there may be an accumulation of risk along the life spectrum, which places pressure on the programming a foetus may have undergone *in utero*, thereby increasing the risk of chronic diseases in adulthood \[[@CIT0032]\]. Therefore, to avert the potential for major physical harm such as in the case of diethylstilboestrol exposure, disclosure is necessary in order to properly monitor HEU individuals into adulthood. Second, one could argue that in addition to childhood malignancies \[[@CIT0016],[@CIT0017],[@CIT0023],[@CIT0036],[@CIT0037]\], there are a myriad of concerning data already surrounding malignancies as well as the mitochondrial \[[@CIT0038]--[@CIT0044]\], mental \[[@CIT0045]--[@CIT0047]\], bone \[[@CIT0048]--[@CIT0051]\], cardiovascular \[[@CIT0052]--[@CIT0054]\] and metabolic \[[@CIT0055]--[@CIT0057]\] health in HEU children as described herein.

#### Malignancy

Though some studies with less follow-up time have reported low cancer incidence rates, which have not exceeded population norms \[[@CIT0016],[@CIT0023],[@CIT0036],[@CIT0037]\], the French EPF recently reported 10 cases of cancer in 53,052 person-years of follow-up as well as an increased risk (hazard ratio (HR)=13.6, 95% CI: 2.5--73.9) associated with didanosine (ddI)+3TC containing regimens versus zidovudine (AZT) monotherapy in HEU children \[[@CIT0018]\]. In a subsequent study with an extended 153,939 person-years of follow-up of HEU children born between 1984 and 2014, the same group reported no differences in the incidence of cancer amongst HEU children compared to the general population but an increased risk with exposure to first trimester ddI (HR=5.5, 95% CI: 2.1--14.4) \[[@CIT0017]\].

#### Mitochondrial toxicity

In France, combination ARVs compared to AZT monotherapy have been found to be associated with mitochondrial dysfunction (relative risk (RR)=2.5, 95% CI: 1.0--6.5, *p*=0.046), and several infants have shown clinical symptomatology \[[@CIT0038],[@CIT0039]\]. Other studies have shown increased mitochondrial DNA in both AZT-exposed versus -unexposed \[[@CIT0040],[@CIT0041]\] as well as HIV/ART-exposed versus -unexposed infants \[[@CIT0042],[@CIT0043]\]. Aberrant mitochondrial morphology has also been demonstrated in infants exposed to *in utero* HIV/ART \[[@CIT0044]\]. What remains unanswered is if and when these early mitochondrial effects translate into poor long-term health outcomes.

#### Mental health

A US study of HEU and perinatally HIV-infected children observed a higher prevalence of mental health problems in HEU children (38% vs. 25%, *p*=0.01) in unadjusted analyses \[[@CIT0045]\]. In the U.S. Child and Adolescent Self-Awareness and Health study of perinatally HIV-infected and HEU youth, both groups exhibited high rates of any psychiatric disorder (49% in HEU youth) \[[@CIT0046]\], and during the one to two years of follow-up, this rate did not decrease (57% at baseline to 54% later) in HEU youth \[[@CIT0047]\].

#### Bone health

Pregnant rhesus macaques have shown compromised intrauterine growth and decreased foetal bone porosity in infants born to high-dose tenofovir (TDF)-treated SIV-infected and -uninfected monkeys \[[@CIT0050],[@CIT0051]\]. The Pediatric HIV/AIDS Cohort Study (PHACS) reported decreased bone mineral content (BMC) in US newborns exposed to antenatal TDF \[[@CIT0049]\]. In addition, the IMPAACT 1084 sub-study of Promoting Maternal and Infant Survival Everywhere (PROMISE) study found that both TDF/emcitritabine/lopinavir/ritonavir (*p*\<0.001) as well as AZT/lamivudine (3TC)/lopinavir/ritonavir-exposed (*p*=0.002) infants showed lower BMC compared to those exposed to AZT monotherapy \[[@CIT0048]\].

#### Cardiovascular and metabolic health

Recent studies have shown decreased left ventricular mass index and early diastolic annular velocity in HIV/ARV-exposed versus -unexposed infants \[[@CIT0052]\]. In addition, increased risk of elevated cardiac troponin T in abacavir-exposed infants (OR=2.33, 95% CI: 1.03--5.26) and decreased risk of elevated N-terminal pro-brain natriuretic peptide in stavudine-exposed infants (OR=0.13, 95% CI: 0.02--0.99) have been reported \[[@CIT0058]\], the long-term significance of either of which remains unclear. Lastly, studies have shown acylcarnitine and amino acid analytes, products of intermediary metabolism, were increased in ARV-exposed infants (43% vs. 0%, *p*=0.02) \[[@CIT0057]\] as well as lower insulin levels and abnormal fuel substrate utilization in HEU infants at six weeks of life \[[@CIT0056]\], which may affect the long-term metabolic health of HEU children.

### Research/Public health considerations

Though they may not be feasible in all settings, prospective cohort studies can provide detailed, closely monitored, and well-described long-term outcomes data on HEU children. In order to continue these studies, it is ethically necessary to consent HEU individuals when they turn 18 since the HEU individual may have been an infant/child at enrolment when original consent was provided by a parent. This re-consenting in adolescence would require disclosure of the child\'s HEU status.

The case against disclosure {#S0002-S20003}
---------------------------

The central argument against disclosure is that the harms of disclosure (psychological stress to the mother and child, the need to maintain privacy of the mother\'s HIV diagnosis, etc.) are greater than any benefit that might occur, or more simply, that there is no benefit due to the fact that no substantial health risks from intrauterine HIV/ARV exposure have been identified. Cumulative evidence strongly supports the continued use of ARVs in pregnancy, and data surrounding harmful HEU child outcomes are reassuring.

### Psychosocial considerations

Though several studies discussed above have indicated psychosocial benefits to the mother and child from disclosure of maternal HIV status, there are almost an equal number citing worsening psychosocial functioning in children of mothers who disclose compared to those whose mothers do not \[[@CIT0005],[@CIT0059]--[@CIT0063]\]. This increased stressor on an already fragile household environment may produce enough psychosocial harm to argue against disclosure. Lower emotional and social functioning \[[@CIT0059]\] as well as increased externalizing behavioural problems \[[@CIT0005]\] have been reported in cross-sectional studies of children whose mothers disclosed. Adolescents whose mothers disclosed may appear to be at risk for early parentification out of a felt need to support their HIV-infected mother \[[@CIT0060],[@CIT0064]\]. Other reports have shown that these adolescents reported higher rates of emotional distress \[[@CIT0028],[@CIT0063]\], high-risk behaviours \[[@CIT0063],[@CIT0065]\] and negative school performance \[[@CIT0062]\] compared to adolescents whose mothers had not disclosed. Disclosure to HEU adolescents may create a layer of unnecessary complexity during a time when the adolescent may not be prepared to properly understand this exposure.

### Physical health considerations

If the risk of physical harm from *in utero* HIV/ARV exposure is not substantial, it may be argued that disclosure is not necessary. What dictates "substantial" is debatable, but many consider outcomes involving birth weight \[[@CIT0066]--[@CIT0075]\], congenital defects \[[@CIT0076]--[@CIT0081]\], early neurodevelopment \[[@CIT0082]--[@CIT0084]\] and growth \[[@CIT0070],[@CIT0075],[@CIT0085]--[@CIT0087]\] as significant, and none of these have demonstrated a clear association with *in utero* HIV/ARV exposure ([Table 3](#T0003){ref-type="table"}). Even pre-term birth, which has been shown in several studies to be associated with ART \[[@CIT0074],[@CIT0089]--[@CIT0092],[@CIT0095]\] is still an early infant outcome and would occur and be managed well before adolescence, the time of disclosure.

###### 

Major studies assessing complications of *in utero* maternal HIV and antiretroviral exposure in HIV-exposed infants

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors (reference)                                                Study subjects/cohort                                      Study design                            Sample size                         Age period studied                              *In utero* exposure of interest                                          outcomes measured                                                                                                                                                                                                                            Results
  ------------------------------------------------------------------ ---------------------------------------------------------- --------------------------------------- ----------------------------------- ----------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Birth outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  *SGA/LBW*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Habib *et al*. 2008 \[88\]                                         Tanzania                                                   Cohort                                  14,444                              Birth                                           ARV-/HIV+ vs. ARV-/HIV-\                                                 SGA at 10th percentile                                                                                                                                                                                                                       Increased risk SGA associated with:\
                                                                                                                                                                                                                                                            ARV+/HIV+ vs. ARV-/HIV-\                                                                                                                                                                                                                                                                                              \*ARV-/HIV+ vs. ARV-/HIV- (OR=1.64, 95% CI: 1.1--2.4)\
                                                                                                                                                                                                                                                            Unknown maternal HIV status vs. ARV-/HIV-                                                                                                                                                                                                                                                                             \*HIV status unknown vs. ARV-/HIV- (OR=1.2, 95% CI: 1.1--1.4)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Infants of treated HIV+ women with similar risk of SGA as infants of HIV- women

  Sperling *et al*. 1998 \[66\]                                      US (PACTG 076)                                             RCT                                     342                                 Birth to 18 months                              Antepartum-Intrapartum-Newborn AZT+ vs. AZT-                             WAZ, LAZ, HCAZ\                                                                                                                                                                                                                              No association between AZT and SGA
                                                                                                                                                                                                                                                                                                                                     SGA                                                                                                                                                                                                                                          

  ECS. 1999 \[67\]                                                   Europe (ECS)                                               Cohort                                  2274                                Birth                                           AZT+ vs. AZT-                                                            LBW (\<2500 g)                                                                                                                                                                                                                               Decreased risk of LBW associated with AZT+ (any) (OR=0.55, 95% CI: 0.39--0.79)

  Chotpitayasunondh *et al*. 2001 \[68\]                             Thailand                                                   RCT                                     395                                 Birth to 18 months                              AZT+ vs. AZT-                                                            WAZ, LAZ, HCAZ                                                                                                                                                                                                                               No differences in mean BW, birth length

  Briand *et al*. 2006 \[85\]                                        Thailand (PHPT-1)                                          RCT                                     1408                                Birth, 6 weeks, 18 months                       AZT+ (≥7.5 weeks) vs. AZT+ (\<7.5 k)                                     WAZ, LAZ, WLZ                                                                                                                                                                                                                                Decreased birth WAZ, WLZ in AZT+ (\>7.5 weeks)

  Siberry *et al*. 2012 \[69\]                                       US (PHACS)                                                 Cohort                                  2010                                Birth to 1 year                                 TDF+ vs. TDF-                                                            SGA, LBW\                                                                                                                                                                                                                                    No association between *in utero* TDF and LBW, SGA or birth LAZ and HCAZ
                                                                                                                                                                                                                                                                                                                                     WAZ, LAZ, HCAZ                                                                                                                                                                                                                               

  Ransom *et al*. 2013 \[70\]                                        US (IMPAACT 1025)                                          Cohort                                  2025                                Birth to 6 months                               TDF+ vs. TDF-                                                            SGA, WAZ                                                                                                                                                                                                                                     No association between *in utero* TDF and SGA (OR=1.09, 95% CI: 0.77--1.52)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No differences in birth WAZ (*p*=0.9)

  Gibb *et al*. 2012 \[71\]                                          Uganda, Zimbabwe (DART)                                    RCT                                     182                                 Birth to 3 year                                 TDF+ vs. TDF-                                                            LBW                                                                                                                                                                                                                                          No difference in rates of LBW between groups

  Tuomala *et al*. 2002 \[72\]                                       US (PACTG 076 & 185, PACTS, WITS, & 3 single sites)        RCT & Cohort                            3266                                Birth                                           any ART vs. no ART\                                                      LBW, VLBW (\<1500 g)                                                                                                                                                                                                                         cART not associated with LBW\
                                                                                                                                                                                                                                                            cART vs.AZT monotherapy\                                                                                                                                                                                                                                                                                              Increased risk of VLBW associated with cART w/PI vs. w/out PI (OR=3.56, 95% CI: 1.04--12.19)
                                                                                                                                                                                                                                                            cART w/out PI vs. AZT monotherapy\                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                            cART w/PI vs. AZT monotherapy\                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                            cART w/PI vs. w/out PI                                                                                                                                                                                                                                                                                                

  Szyld *et al*. 2006 \[73\]                                         Latin America & Caribbean (NISDI)                          Cohort                                  681                                 Birth                                           PI- vs. NNRTI- vs. 1--2 NRTI-based cART                                  LBW                                                                                                                                                                                                                                          No increased risk of LBW (OR=1.5, 95% CI: 0.7--3.2 for PI; OR=0.6, 95% CI: 0.3--1.5 for NNRTI)

  Watts *et al*. 2013 \[74\]                                         US (PHACS)                                                 Cohort                                  1869                                Birth                                           cART with PI vs. mono/dual therapy ART\                                  SGA at 10th percentile                                                                                                                                                                                                                       No association between SGA and cART
                                                                                                                                                                                                                                                            cART with NNRTI vs. mono/dual therapy ART\                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                            cART with ≥3 NRTIs vs. mono/dual therapy ART\                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                            cART initiated pre-pregnancy vs. cART initiated after 1^st^ trimester                                                                                                                                                                                                                                                 

  Nielsen-Saines *et al*. 2012 \[75\]                                Africa, Thailand, India, Brazil (ACTG 5190/IMPAACT 1054)   Cohort                                  236                                 Birth to 18 months                              cART vs. AZT (≥7 days) vs. AZT (intrapartum only)                        SGA                                                                                                                                                                                                                                          No differences in SGA between groups

  Chen *et al*. 2012 \[89\]                                          Botswana                                                   Cohort                                  33,148                              Birth                                           HIV+ vs. HIV-\                                                           SGA at 10th percentile                                                                                                                                                                                                                       Increased risk of SGA associated with:\
                                                                                                                                                                                                                                                            cART+ (initiated pre-pregnancy)/HIV+ vs.\                                                                                                                                                                                                                                                                             *\*in utero* HIV exposure (OR=1.8, 95% CI: 1.7--1.9)\
                                                                                                                                                                                                                                                            all other/HIV+\                                                                                                                                                                                                                                                                                                       \*cART+ (initiated pre-pregnancy)/HIV+ vs. all other/HIV+ (OR=1.8, 95% CI: 1.6--2.1)\
                                                                                                                                                                                                                                                            cART+ vs. AZT monotherapy\                                                                                                                                                                                                                                                                                            \**in utero* cART vs. AZT monotherapy (OR=1.5, 95% CI: 1.2--1.9)\
                                                                                                                                                                                                                                                            cART+ (initiated pre-pregnancy) vs. cART+ (initiated during pregnancy)                                                                                                                                                                                                                                                \**in utero* cART+ initiated pre-pregnancy vs. during pregnancy (OR:1.3, 95% CI: 1.0--1.5)

  *Preterm birth*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  *Combination ART exposure*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  ECS. 2003 \[76\]                                                   Europe (ECS)                                               Cohort                                  2414                                Birth                                           cART vs. no ART vs. AZT monotherapy                                      Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth (OR=2.66, 95% CI: 1.52--4.67 for cART without PI; OR=4.14, 95% CI: 2.36--7.23 for cART with PI) with cART

  Townsend *et al*. 2010 \[90\]                                      US, Europe (PSD, ECS, NSHPC)                               Pooled analysis of registry & cohorts   19,585                              Birth                                           cART vs. dual therapy cART                                               Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth (OR=1.49, 95% CI: 1.19--1.87) with cART vs. dual therapy cART

  Chen *et al*. 2012 \[88\]                                          Botswana                                                   Cohort                                  13,181                              Birth                                           cART vs. AZT monotherapy\                                                Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth with cART (OR=1.4, 95% CI: 1.2--1.8) and pre-pregnancy cART initiation (OR=1.2, 95% CI: 1.1--1.4)
                                                                                                                                                                                                                                                            pre-pregnancy cART initiation vs. all others                                                                                                                                                                                                                                                                          

  Sibiude *et al*. 2012 \[91\]                                       France (EPF)                                               Cohort                                  1253                                Birth                                           cART vs. AZT monotherapy\                                                Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth with cART (OR=1.69, 95% CI: 1.38--2.07)\
                                                                                                                                                                                                                                                            Ritonavir boosted PI vs. non-ritonavir boosted PI                                                                                                                                                                                                                                                                     Increased risk preterm birth with ritonavir boosted PI (OR=2.03; 95% CI: 1.06--3.89)

  Short *et al*. 2014 \[92\]                                         UK                                                         Cohort                                  331                                 Birth                                           cART vs. AZT monotherapy                                                 Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth with cART (OR=5.0, 95% CI: 1.5--16.8)

  Lopez *et al*. 2012 \[93\]                                         Spain                                                      Matched cohort                          1557                                Birth                                           HIV+/ARV+ or ARV- vs. HIV-\                                              Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth with maternal HIV infection (ARV+/−) (OR=2.5, 95% CI: 1.5--3.9)\
                                                                                                                                                                                                                                                            cART during 2^nd^ half of pregnancy vs. untreated                                                                                                                                                                                                                                                                     Increased risk iatrogenic preterm birth with cART during 2^nd^ half of pregnancy (OR=6.16, 95% CI: 1.42--26.80)

  *PI exposure*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Cotter *et al*. 2006 \[[@CIT0094]\]                                US                                                         Registry                                1337                                Birth                                           PI-based cART vs. non PI-based cART\                                     Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth (OR=1.8, 95% CI: 1.1--3.0) for PI vs. non PI-based cART\
                                                                                                                                                                                                                                                            cART vs. AZT monotherapy\                                                                                                                                                                                                                                                                                             No increased risk for preterm birth with cART vs. AZT monotherapy or ART vs. no ART
                                                                                                                                                                                                                                                            Any ART vs. none                                                                                                                                                                                                                                                                                                      

  Schulte *et al*. 2007 \[95\]                                       US (PSD)                                                   Registry                                8793                                Birth                                           PI-based cART vs. dual therapy ART\                                      Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth (OR=1.21, 95% CI: 1.04--1.40)\
                                                                                                                                                                                                                                                            No ART vs. dual therapy ART                                                                                                                                                                                                                                                                                           Increased risk preterm birth (OR=1.16, 95% CI: 1.02--1.32)

  Grosch-Woerner *et al*. 2008 \[[@CIT0096]\]                        Germany                                                    Cohort                                  183                                 Birth                                           PI-based cART vs. AZT monotherapy                                        Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth (OR=3.4, 95% CI: 1.1--10.2) with PI-based cART

  Szyld *et al*. 2006 \[73\]                                         Latin America and Caribbean (NISDI)                        Cohort                                  681                                 Birth                                           PI- vs. NNRTI- vs. 1-2 NRTI-based ART                                    Preterm birth                                                                                                                                                                                                                                No increased risk of preterm birth (OR=1.1, 95% CI: 0.5--2.8 for PI; OR=0.6, 95% CI: 0.2--1.7 for NNRTI)

  Shapiro *et al*. 2010 \[[@CIT0097]\]                               Botswana                                                   RCT                                     709                                 Birth                                           PI- vs. triple NRTI- vs. NNRTI- based ART                                Preterm birth (secondary outcome)                                                                                                                                                                                                            Increased rate preterm birth in PI arm (23% vs. 15% vs. 10%)

  Watts *et al*. 2013 \[74\]                                         US (PHACS)                                                 Cohort                                  1869                                Birth                                           1^st^ trimester PI vs. NNRTI vs. ≥3 NRTIs-based ART                      Preterm birth                                                                                                                                                                                                                                Increased risk preterm birth with 1st trimester PI (OR=1.55, 95% CI: 1.16--2.07)

  **Congenital anomalies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  ECS. 2003 \[76\]                                                   Europe (ECS)                                               Cohort                                  2414                                Birth                                           Any ART vs. no ART                                                       Any congenital anomaly                                                                                                                                                                                                                       Similar patterns and prevalence rates of congenital anomalies in ART vs. no ART exposure (1.4% vs. 1.6%, *p*=0.762)

  Townsend *et al*. 2009 \[77\]                                      UK                                                         Surveillance                            8242                                Birth                                           Late vs. early ART exposure\                                             Any congenital anomaly                                                                                                                                                                                                                       Overall prevalence of congenital anomalies=2.2%, 95% CI: 2.5--3.2%\
                                                                                                                                                                                                                                                            PI- vs. NNRTI- vs. NRTI only- vs. 2 class-cART                                                                                                                                                                                                                                                                        No differences in congenital anomalies by timing or class of ART exposure

  Ford *et al*. 2014 \[98\]                                          --                                                         Pooled analysis                         2026 (pooled overall prevalence)\   Birth                                           EFV                                                                      Any congenital anomaly\                                                                                                                                                                                                                      Overall prevalence of congenital anomalies=1.63%, 95% CI: 0.78--2.48%\
                                                                                                                                                                        11,325 (pooled RR)                                                                                                                                           NTD                                                                                                                                                                                                                                          No differences in overall congenital anomalies between EFV vs. non-EFV ART; (RR=0.78, 95% CI: 0.56--1.08)

  Watts *et al*. 2011 \[78\]                                         PACTG 316                                                  Cohort                                  1408                                Birth                                           Multiple ARVs                                                            Any congenital anomaly                                                                                                                                                                                                                       Overall prevalence of congenital anomalies=4.2%, 95% CI: 3.3--5.4%

  Liu *et al*. 2014 \[79\]                                           South Africa Zambia                                        Cohort                                  600                                 Birth to 1 year                                 cART since conception                                                    Any congenital anomaly                                                                                                                                                                                                                       Overall prevalence of congenital anomalies=6.2%; Prevalence of major congenital anomalies=2.2%

  Sibiude *et al*. 2014 \[80\]                                       France                                                     Cohort                                  13,124                              Birth to 18 months                              Multiple ARVs                                                            Any congenital anomaly as defined by EUROCAT and by MACDP                                                                                                                                                                                    Overall prevalence of congenital anomalies=4.4%, 95% CI: 4.0--4.7% using EUROCAT

  Knapp *et al*. 2012 \[99\]                                         IMPAACT 1025                                               Cohort                                  1112                                Birth                                           EFV                                                                      Any congenital anomaly                                                                                                                                                                                                                       Overall prevalence of congenital anomalies=5.5%, 95% CI: 4.22--6.99. Increased risk of congenital anomaly with 1st trimester EFV (OR=2.84, 95% CI: 1.13--7.16)

  Antiretroviral Pregnancy Registry Executive Summary 2015 \[100\]   US (Antiretroviral Pregnancy Registry)                     Registry                                7135                                Birth                                           Any 1^st^ trimester ART                                                  Any congenital anomaly                                                                                                                                                                                                                       Overall prevalence of congenital anomalies=2.8%, 95% CI: 2.5--3.3%

  Williams *et al*. 2014 \[101\]                                     PHACS                                                      Cohort                                  2580                                Birth                                           Multiple ARVs                                                            Any congenital anomaly                                                                                                                                                                                                                       Overall prevalence of congenital anomalies=6.8%, 95% CI: 5.9--7.8%

  **Endocrine/metabolic**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  *Infant/Child growth*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  ECS. 2005 \[102\]                                                  Europe (ECS)                                               Cohort                                  1912                                Birth to 18 months                              cART vs. No/AZT monotherapy                                              WAZ, LAZ, HCAZ                                                                                                                                                                                                                               Decreased WAZ \[β=(−0.10), *p*=0.019\], LAZ \[β=(−0.12), *p*=0.008\], and HCAZ \[β=(−0.14), *p*=0.001\] associated with cART

  Briand *et al*. 2006 \[85\]                                        Thailand (PHPT-1)                                          RCT                                     1408                                Birth, 6 weeks, 18 months                       AZT+ (≥7.5 weeks) vs. AZT+ (\<7.5 weeks)                                 WAZ, LAZ, WLZ                                                                                                                                                                                                                                No differences in 6 weeks or 18 months WAZ, LAZ, WLZ between groups

  Ibieta *et al*. 2009 \[86\]                                        Spain (FIPSE)                                              Cohort                                  601                                 Birth to 2 years                                ARV+/HIV+ vs. ARV-/HIV-\                                                 WAZ, LAZ, HCAZ                                                                                                                                                                                                                               No differences in WAZ, LAZ, HCAZ between groups
                                                                                                                                                                                                                                                            ARV-/HIV+ vs. ARV+/HIV+\                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                            cART w/PI+ vs. cART w/out PI                                                                                                                                                                                                                                                                                          

  Nielsen-Saines *et al*. 2012 \[75\]                                US (ACTG 5190)\                                            Cohort                                  236                                 Birth to 18 months                              cART vs. AZT (≥7 days) vs. AZT (intrapartum only)                        WAZ, LAZ, HCAZ                                                                                                                                                                                                                               No differences in WAZ, LAZ, HCAZ by ARV exposure
                                                                     Africa, Thailand, India, Brazil (IMPAACT 1054)                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Siberry *et al*. 2012 \[69\]                                       US (PHACS)                                                 Cohort                                  2010                                Birth, 1 year                                   TDF+ vs. TDF-                                                            WAZ, LAZ, HCAZ                                                                                                                                                                                                                               Decreased LAZ \[ß=(−0.17) vs. (−0.03), *p*=0.04\] and HCAZ (ß=0.17 vs.0.42, *p*=0.02) at 1 year associated with *in utero* TDF

  Neri *et al*. 2013 \[87\]                                          US                                                         Matched case control                    111                                 Birth to 2 year                                 cART+/HIV+ vs. matched cART-/HIV-\                                       WAZ, WLZ                                                                                                                                                                                                                                     No differences in growth between HEU and HIV-unexposed infants
                                                                                                                                                                                                                                                            cART+/HIV+ vs. NHANES                                                                                                                                                                                                                                                                                                 

  Ransom *et al*. 2013 \[70\]                                        US (IMPAACT 1025)                                          Cohort                                  2025                                Birth, 6 months                                 TDF+ vs. TDF-                                                            WAZ                                                                                                                                                                                                                                          No differences in WAZ at 6 months between groups

  *Mitochondrial toxicity*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Perinatal Safety Review Working Group. 2000 \[[@CIT0103]\]         US (PACTG 076 & 185, WITS, PACTS, PSD, PHS)                Cohort                                  23,265                              Birth to \<60 months                            AZT monotherapy\                                                         Mortality from mitochondrial dysfunction                                                                                                                                                                                                     No deaths or associated signs/symptoms suggestive of or proven to result from mitochondrial dysfunction
                                                                                                                                                                                                                                                            AZT-3TC\                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                            Other                                                                                                                                                                                                                                                                                                                 

  Barrett *et al*. 2003 \[39\]                                       France                                                     Cohort                                  4426                                Birth to 18 months                              ART (any)+/HIV+ vs.\                                                     Mitochondrial dysfunction classified as: *Established* (compatible clinical symptoms + Decrease in OXPHOS or Abnormal mt morphology) vs. *Possible* (compatible clinical symptoms + hyperlactatemia or minor mt morphologic abnormalities)   12 subjects with "Established" mt dysfunction; 14 with "Possible" mitochondrial dysfunction\
                                                                                                                                                                                                                                                            ART-/HIV+                                                                                                                                                                                                                                                                                                             Increased incidence of mitochondrial dysfunction\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Combination NRTIs (vs. AZT monotherapy) associated with increased risk of mitochondrial dysfunction (RR=2.5, 95% CI: 1.0--6.5, *p*=0.046)

  Aldrovandi *et al*. 2010 \[40\]                                    US (WITS, PACTG 1009)                                      Cohort                                  624                                 Birth to 5 year                                 AZT-3TC+/HIV+ vs. AZT+/HIV+ vs.\                                         Mitochondrial DNA content                                                                                                                                                                                                                    Decreased mitochondrial DNA levels\
                                                                                                                                                                                                                                                            AZT-/HIV+ vs.\                                                                                                                                                                                                                                                                                                        (AZT or AZT-3TC+/HIV+ vs. AZT-/HIV-)\
                                                                                                                                                                                                                                                            AZT-/HIV-                                                                                                                                                                                                                                                                                                             Increased mitochondrial DNA (AZT+/HIV+ vs. AZT-/HIV+ & AZT-3TC+/HIV+ vs. AZT+/HIV+)

  Brogly *et al*. 2010 \[[@CIT0104]\]                                US (IMPAACT)                                               Cohort                                  982                                 Birth to 1 year                                 Any ART+ vs. ART-\                                                       Possible mitochondrial dysfunction defined as compatible clinical signs using EPF definition                                                                                                                                                 3 subjects with possible mt dysfunction\
                                                                                                                                                                                                                                                            Any NRTI+ vs. NRTI-\                                                                                                                                                                                                                                                                                                  No association between ART and mitochondrial dysfunction
                                                                                                                                                                                                                                                            3TC, AZT, ABC, d4T, ddI, & TDF individually                                                                                                                                                                                                                                                                           

  McComsey *et al*. 2008 \[42\]                                      US (ACTG 5084)                                             Cohort                                  136                                 Birth                                           cART+/HIV+ vs.\                                                          Mitochondrial DNA content; Respiratory chain activity                                                                                                                                                                                        Increased mitochondrial DNA levels\
                                                                                                                                                                                                                                                            cART-/HIV-                                                                                                                                                                                                                                                                                                            No difference in Complex II:IV ratio

  Côté *et al*. 2008 \[43\]                                          Canada                                                     Cohort                                  154                                 Birth to 6 months                               cART+/HIV+ vs.\                                                          Mitochondrial DNA content                                                                                                                                                                                                                    Increased mitochondrial DNA levels
                                                                                                                                                                                                                                                            cART-/HIV-                                                                                                                                                                                                                                                                                                            

  Kunz *et al*. 2012 \[41\]                                          Tanzania                                                   Cohort                                  83                                  Birth                                           AZT+/sdNVP+/HIV+ vs.\                                                    Mitochondrial DNA content; Mitochondrial deletion dmtDNA4977                                                                                                                                                                                 Increased mitochondrial DNA levels\
                                                                                                                                                                                                                                                            AZT-/sdNVP+/HIV+                                                                                                                                                                                                                                                                                                      No deletion of dmtDNA4977

  *Intermediary Metabolism*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Kirmse *et al*. 2013 \[57\]                                        US                                                         State Registry                          2371                                Birth                                           HIV+/ARV+ vs. HIV-/ARV-                                                  Abnormal newborn metabolic screen and acylcarnitine profiles                                                                                                                                                                                 Increased rate of abnormal newborn metabolic screen in HIV-exposed infants compared to general population (2.2 vs. 1.2%, *p*=0.0003);\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Increased frequency of abnormal acylcarnitine profiles (43 vs. 0%, *p*=0.02)

  Jao *et al*. 2015 \[56\]                                           Cameroon                                                   Cohort                                  366                                 Birth to 6 weeks                                HIV+/ARV+ vs. HIV-/ARV-\                                                 Pre-prandial infant insulin and HOMA-IR\                                                                                                                                                                                                     Lower pre-prandial insulin in postnatal AZT HEU vs. HUU infants (β: −0.116, *p*=0.012) and in postnatal NVP HEU vs. HUU infants\
                                                                                                                                                                                                                                                            Postnatal AZT HEU vs. Postnatal NVP HEU vs. HUU                          Acylcarnitines and branched-chain amino acids                                                                                                                                                                                                (β: −0.070, *p*=0.022)

  *Bone Health*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Vigano *et al*. 2011 \[[@CIT0105]\]                                Italy                                                      Cohort                                  68                                  Birth to 6 year                                 TDF+ vs. TDF-                                                            Tibial SOS via ultrasound\                                                                                                                                                                                                                   No differences in tibial SOS\
                                                                                                                                                                                                                                                                                                                                     Bone markers                                                                                                                                                                                                                                 No differences in bone markers

  Mora *et al*. 2012 \[[@CIT0106]\]                                  Italy                                                      Cohort                                  131                                 Birth, 4 months, 12 months                      ARV+/HIV+ vs. ARV-/HIV-                                                  Tibial SOS via ultrasound\                                                                                                                                                                                                                   No differences in tibial SOS\
                                                                                                                                                                                                                                                                                                                                     Bone markers                                                                                                                                                                                                                                 No differences in bone markers

  Siberry *et al*. 2015 \[49\]                                       US (PHACS)                                                 Cohort substudy                         143                                 Birth to 1 month                                TDF+ vs. TDF-                                                            BMC via bone DXA                                                                                                                                                                                                                             Mean BMC decreased in TDF-exposed infants 56.0 vs. 63.8g *p*=0.002)

  Siberry *et al*. 2016 \[48\]                                       Multi-national (IMPAACT PROMISE 1084 substudy)             RCT substudy                            362                                 Birth to 21 days of life                        AZT monotherapy vs.\                                                     Whole body BMC via bone DXA                                                                                                                                                                                                                  Lower whole body BMC in:\
                                                                                                                                                                                                                                                            TDF/FTC/Lop/r vs.\                                                                                                                                                                                                                                                                                                    TDF/FTC/Lop/r vs. AZT monotherapy (*p*\<0.001)\
                                                                                                                                                                                                                                                            AZT/3TC/Lop/r                                                                                                                                                                                                                                                                                                         AZT/3TC/Lop/r vs. AZT monotherapy (*p*=0.002)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No difference between TDF/FTC/Lop/r vs. AZT/3TC/Lop/r arms

  **Cardiovascular**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Lipschultz *et al*. 2000 \[[@CIT0107]\]                            US (PHACS)                                                 Cohort                                  611                                 Birth to 15 months                              Continuous AZT+/HIV+ vs.\                                                Cardiac structure and function via echo                                                                                                                                                                                                      No differences in cardiac structure or left ventricular function
                                                                                                                                                                                                                                                            AZT-/HIV+                                                                                                                                                                                                                                                                                                             

  Cade *et al*. 2012 \[52\]                                          US                                                         Matched cohort                          60                                  8 to 12 year olds                               ARV+/HIV+ vs. ARV-/HIV-                                                  LV EDV\                                                                                                                                                                                                                                      Decreased LV mass index and early diastolic annular velocity in HIV/ARV-exposed children
                                                                                                                                                                                                                                                                                                                                     LV mass                                                                                                                                                                                                                                      

  Wilkinson *et al*. 2013 \[58\]                                     US (PHACS)                                                 Cohort                                  338                                 Birth to 5 year                                 Specific ARVs                                                            Cardiac biomarkers: hsCRP, cTnT, NT-proBNP                                                                                                                                                                                                   Increased risk of elevated cTnT levels in ABC-exposed infants (OR=2.33, 95% CI: 1.03--5.26)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Decreased risk of elevated NT-proBNP in d4T-exposed infants (OR=0.13, 95% CI: 0.02--0.99)

  **Neurodevelopmental/mental health**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Williams *et al*. 2010 \[82\]                                      US (PACTG 219)                                             Cohort                                  1840                                Birth to 2 year                                 ARV+/HIV+ vs. ARV-/HIV+                                                  MDI & PDI scores from Bayley Scales of Infant Development                                                                                                                                                                                    No differences in MDI or PDI scores

  Sirois *et al*. 2013 \[83\]                                        US (PHACS)                                                 Cohort                                  374                                 Birth to 15 months                              cART+/HIV+ vs. no ART/HIV+\                                              Bayley Scales of Infant Development Version III                                                                                                                                                                                              No differences in mean scores for any of the 5 domains within Bayley III
                                                                                                                                                                                                                                                            cAtRT+/HIV+ vs. AZT monotherapy/HIV+\                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                            PI- vs. NNRTI- vs. NRTI only based cART                                                                                                                                                                                                                                                                               

  Kerr *et al*. 2014 \[108\]                                         Thailand, Cambodia                                         Cohort                                  333                                 Mean age 7.6 years                              ART+/HIV+ vs. ARV-/HIV-                                                  Wechsler Intelligence Scale; Stanford Binet II Memory Tests                                                                                                                                                                                  Verbal IQ: Adjusted mean difference =−6.13, *p*=0.004\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Full Scale IQ: Adjusted mean difference =−4.57, *p*=0.03\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Stanford Binet Bead Memory: Adjusted mean difference =−3.72, *p*=0.01

  Nozyce *et al*. 2014 \[84\]                                        US (PHACS)                                                 Cohort                                  739                                 5 to 13 year olds                               PI-based cART vs.\                                                       WPPSI-III (5 year old)\                                                                                                                                                                                                                      No associations between any ARV regimen/class and cognitive or academic outcomes
                                                                                                                                                                                                                                                            NNRTI-based cART vs.\                                                    WASI (7, 9, 11 and 13 year old)\                                                                                                                                                                                                             
                                                                                                                                                                                                                                                            non-cART regimen vs.\                                                    WIAT-II-A                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                            no ARV                                                                                                                                                                                                                                                                                                                

  Malee *et al*. 2011 \[45\]                                         US (PHACS)                                                 Cohort                                  416 total (121 HEU)                 55% less than 12 years old                      Perinatally HIV-infected and HEU youth                                   Mental Health problems using BASC-2 Self-Report of Personality and BASC-2 Parent Rating Scale                                                                                                                                                Rates of mental health problems higher in HEU vs. perinatally HIV-infected youth (38% vs. 25%, *p*=0.01)

  Mellins *et al*. 2012 \[47\]                                       US (CASAH)                                                 Cohort                                  340 total (134 HEU)                 Mean age 12.2 years (SD=2.3)                    Perinatally HIV-infected and HEU youth                                   Psychiatric diagnoses using DISC-IV                                                                                                                                                                                                          High rates of overall psychiatric disorders in HEU youth (49%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No change in these rates over longitudinal follow-up (mean 18.5 years follow-up)

  **Oncologic**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Hanson *et al*. 1999 \[37\]                                        US (PACTG 076 & 219, WITS)                                 Cohort                                  727                                 Range: \[Birth-1 month\] -- \[Birth-6 years\]   AZT                                                                      Any malignancy                                                                                                                                                                                                                               Overall RR of tumour=0.0, 95% CI: 0--17.6

  Brogly *et al*. 2006 \[36\]                                        US (PACTG 219)                                             Cohort                                  2077                                Not reported                                    Multiple regimens                                                        Any malignancy                                                                                                                                                                                                                               One incident of cancer in 7871 person years of follow-up (incidence rate=0.127 per 1000 person-years, 95% CI: 0.003--0.708)

  Hankin *et al*. 2007 \[23\]                                        UK (NSHPC)                                                 Surveillance                            2612                                Not reported                                    Multiple regimens                                                        Any malignancy                                                                                                                                                                                                                               No cases of cancer over 6593 child-years of follow-up

  Benhammou *et al*. 2008 \[18\]                                     France (EPF)                                               Cohort                                  9127                                53,052 person years follow-up                   Multiple regimens                                                        Any malignancy                                                                                                                                                                                                                               10 cases of cancer in 53,052 person-years of follow-up\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Increased risk of cancer (HR=13.6, 95% CI: 2.5--73.9) with ddI+3TC containing regimens vs. AZT monotherapy

  Hleyhel *et al*. 2016 \[17\]                                       France (EPF)                                               Cohort                                  15,163                              153,939 person years follow-up                  Multiple regimens                                                        Any malignancy                                                                                                                                                                                                                               21 cases of cancer in 153,939 person years of follow-up\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No difference in cancer incidence amongst HEU vs. general population\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Increased risk of cancer (HR=2.5, 95% CI: 1.01--5.19) with ddI exposure and significantly increased risk with 1st trimester ddI (HR=5.5, 95% CI: 2.1--14.4)

  Ivy *et al*. 2015 \[16\]                                           US                                                         State registry/surveillance             3087                                1 to 16 years                                   Multiple regimens                                                        Any malignancy                                                                                                                                                                                                                               4 cases of cancer in 3087 HIV-exposed children (29,099 person years) between 1995 and 2010;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  13.7 per 100,000 person years cancer incidence rate (95% CI: 3.7--35.2)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3TC=lamivudine; ABC=abacavir; ART=antiretroviral therapy; ARV=antiretroviral; AZT=zidovudine; cART=combination antiretroviral therapy; BASC-2=Behavior Assessment System for Children, 2nd edition; CASAH=Child and Adolescent Self-Awareness and Health; CI=Confidence Interval; cTnT=cardiac Troponin T; d4T=stavudine; DART=Development of AntiRetroviral Therapy in Africa; ddI=didanosine; DISC-IV=Diagnostic Interview Schedule for Children; DXA=Dual Energy X Ray Absorptiometry; ECS=European Collaborative Study; EDV=end diastolic volume; EFV=efavirenz; EPF=Enquête Périnatale Française; EUROCAT=European Surveillance of Congenital Anomalies; FIPSE=Fundación para la Investigación y la Prevención del Sida en Espana; HCAZ=Head Circumference for Age z score; HEU=HIV-exposed uninfected; HOMA-IR=Homeostatic Model Assessment-Insulin Resistance; HR=Hazard Ratio; hsCRP=high sensitivity C-reactive Protein; HUU=HIV-unexposed uninfected; IMPAACT=International Maternal Pediatric Adolescent AIDS Clinical Trials Group; LAZ=Length for Age z score; LBW=low birth weight; LV=left ventricular; MACDP=Metropolitan Atlanta Congenital Defects Program; MDI=Mental Developmental Index; NHANES=National Health and Nutrition Examination Survey; NSHPC=National Study of HIV in Pregnancy and Childhood; NISDI=National Institute of Child Health and Human Development International Site Development Initiative; NNRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor; NTD=neural tube defect; NT-proBNP=N-terminal pro-brain natriuretic peptide; OR=odds ratio; PACTG=Pediatric AIDS Clinical Trials Group; PDI=Psychomotor Developmental Index; PHACS=Pediatric HIV/AIDS Cohort Study; PHPT-1=Perinatal HIV Prevention Trial-1; PHS=Pediatric HIV Surveillance; PI=protease inhibitor; PROMISE=Promoting Maternal and Infant Survival Everywhere; PSD=Pediatric Spectrum of HIV Disease Project; RCT=randomized controlled trial; RR=relative risk; sdNVP=single dose nevirapine; SD=standard deviation; SGA=small-for-gestational age; SOS=speed of sound; TDF=Tenofovir disoproxil fumarate; UK=United Kingdom; US=United States; VLBW=very low birth weight; WASI=Wechsler Abbreviated Scale of Intelligence; WAZ=weight for age z score; WIAT-II-A=Wechsler Individual Achievement Test -- Version II Abbreviated; WITS=Women and Infants Transmission Study; WLZ=weight for length z score; WPPSI-III=Wechsler Preschool & Primary Scale of Intelligence-Version III

#### Birth weight

Despite one large study in Botswana which reported an increased risk for small-for-gestational age (SGA)outcomes in HEU infants \[[@CIT0088]\] (odds ratio (OR) for SGA=1.5, 95% CI: 1.2--1.9), the vast majority of reports have not found a consistent association between *in utero* HIV/ARVs and low birth weight (LBW) or SGA outcomes. Exposure to antenatal AZT has not been found to be associated with SGA in the United States \[[@CIT0066]\] or LBW in Europe \[[@CIT0067]\]. In addition, studies in the United States \[[@CIT0072],[@CIT0074]\] and another multi-country study \[[@CIT0075]\] have reported no associations between antenatal ART and LBW/SGA. A large study in Latin America also did not find risks for LBW when comparing classes of ARVs \[[@CIT0073]\]. Lastly, two US studies \[[@CIT0069],[@CIT0070]\] did not find increased risks for SGA, and one Ugandan study did not find increased risks for LBW \[[@CIT0071]\] with intrauterine TDF exposure.

#### Congenital defects

In general, there has not been evidence for an increased rate of birth defects (overall rates 1.4--6.2%) associated with HIV/ARV exposure \[[@CIT0076]--[@CIT0081],[@CIT0098],[@CIT0099]\]. The two largest surveillance registries for congenital anomalies in the UK \[[@CIT0077]\] and the United States \[[@CIT0100]\] have found low rates of birth defects consistent with other cohorts in Europe \[[@CIT0076]\] and the United States \[[@CIT0078]\]. Few reports have emerged from low-income countries, but one pilot ART registry from South Africa and Zambia identified a 6.2% prevalence rate for all and 2.2% for major congenital anomalies \[[@CIT0079]\]. Despite earlier reports in humans revealing neural tube defects in infants exposed to efavirenz (EFV) early in gestation \[[@CIT0099],[@CIT0109]\], a more recent meta-analysis of 2026 infants countered these results and found no risk (RR=0.78, 95% CI: 0.56--1.08) \[[@CIT0093]\]. In addition, the French EPF \[[@CIT0080]\] and a recent US study \[[@CIT0101]\] found overall low rates of congenital anomalies associated with EFV.

#### Neurodevelopment

The Pediatric AIDS Clinical Trial Group (PACTG) 219 noted no differences in mental or psychomotor developments in 1840 HIV/ARV-exposed versus -unexposed children \[[@CIT0082]\]. Similar findings were found in the PHACS cohort when assessing the effects of ART exposure as well as differing ART class regimens \[[@CIT0083]\]. A more recent study within PHACS also evaluated cognitive outcomes in older HEU children and did not find associations between any perinatal ART class regimens and cognitive and academic scores \[[@CIT0084]\]. One study from Thailand reported small reductions in Wechsler Intelligence Scale testing comparing HEU to HUU children but acknowledged the uncertainty around the long-term clinical significance of these findings \[[@CIT0108]\].

#### Growth

With the exception of a few studies \[[@CIT0069],[@CIT0102]\], most large studies have not reported problems with early postnatal growth after *in utero* HIV/ARV exposure \[[@CIT0070],[@CIT0075],[@CIT0085]--[@CIT0087]\]. A Thai study found no differences in weight-for-age, weight-for-length, or length-for-age z scores between infants exposed to \<7.5 versus ≥7.5 weeks of AZT \[[@CIT0085]\]. A Spanish cohort reported similar findings when evaluating HIV/ARV-exposed versus HIV-unexposed infants and HIV- versus HIV/ARV-exposed infants \[[@CIT0086]\]. A multi-national study had comparable results when examining ART versus AZT monotherapy exposure \[[@CIT0075]\].

### Research/public health considerations

While large prospective research cohorts may be the most comprehensive method to monitor HEU children long-term, they require re-consenting an HEU adolescent and disclosure of HEU status, rendering the feasibility and sustainability of these in all settings challenging. Surveillance programmes with linkage systems for the monitoring of major events may be used instead for long-term monitoring, particularly in resource-constrained settings where the largest proportion of HEU children reside, and would not require disclosure in most circumstances.

Conclusions: to disclose or not to disclose {#S0003}
===========================================

As we confront the many unknowns outlined above -- the continued high rates of HIV infection in women globally with an increasing and aging population of HEU children -- the tensions surrounding disclosure will need to be considered carefully. Clinicians in both high- and low-resource settings face the difficulty of balancing the need to respect a mother\'s rights to privacy and prevent further familial psychosocial harm versus the potential benefits to the HEU adolescent and his/her family from disclosure of exposures \[[@CIT0012]\]. In these settings, careful assessment (and re-assessments) of the risk/benefit ratio, the HEU individual\'s changing and maturing needs, and the mother\'s need for privacy should be considered during the discussion of whether to disclose or not. At present, it is not clear that we have sufficient evidence on whether long-term adverse effects are associated with *in utero* HIV/ARV exposures, making it difficult to mandate universal disclosure. If evidence for a particularly threatening complication from intrauterine HIV/ARV exposure unsurfaces through research, countries may grapple seriously with how best to manage and address this issue, particularly in areas where healthcare infrastructures are already fragile, or health literacy is low. Data on long-term reproductive health effects, immunologic dysfunction, risk of adult onset malignancies, cardiovascular disease, or neurodevelopmental and mental health disorders in adulthood are still inconclusive with no published reports in HEU adults. To meet this void of evidence, research and long-term monitoring likely needs to be continued, and there is general consensus among health professionals and parents of HEU children that more data need to be collected on the long-term health of HEU individuals \[[@CIT0026]\]. Research methods using anonymized surveillance systems linked to other national registries will prove indispensable as data are gathered to understand whether *in utero* HIV/ARV exposure may result in long-term harm, but prospective research cohorts evaluating this question will need to contend with the need for disclosure to HEU individuals in order to continue long-term follow-up into adulthood -- a conundrum where the rationale for the research clashes with the reasons for not mandating universal disclosure at present.

As more countries adopt electronic medical record (EMR) systems, the HEU status of an individual will be an important piece of the health record which will follow the infant not only through childhood and adolescence but also adulthood, which may cause disclosure to be a moot point once young adults access their records. With increasing understanding of the influence of early intrauterine exposures on long-term health outcomes, this practice of early and continued documentation should become the standard as EMR systems expand, potentially rendering disclosure an easier and more natural process for parents/caregivers. Permanent documentation via EMR of perinatal exposures may also improve research and surveillance/registry efforts which are required in order to continue monitoring into adulthood and ultimately gather essential data which are still lacking. Thus, clinicians and researchers should continue to approach the dialogue around mother--child disclosure with sensitivity, an understanding of maternal needs in addition to a child/adolescent\'s development and readiness to hear information, and a cogent consideration of the evolving risks and benefits as new information becomes available but work to maintain documentation of an individual\'s perinatal HIV/ARV exposures as a vital part of his/her medical records. As more long-term adult safety data on *in utero* HIV/ARV exposures become available, these decisions may become clearer, but for the moment, they remain complex and multi-faceted.
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